| 000 | 01384 a2200337 4500 | ||
|---|---|---|---|
| 001 | 1315354454 | ||
| 005 | 20250317111607.0 | ||
| 008 | 250312042016xx 30 eng | ||
| 020 | _a9781315354453 | ||
| 037 |
_bTaylor & Francis _cGBP 48.99 _fBB |
||
| 040 | _a01 | ||
| 041 | _aeng | ||
| 072 | 7 |
_aTDCW _2thema |
|
| 072 | 7 |
_aMBNS _2thema |
|
| 072 | 7 |
_aPS _2thema |
|
| 072 | 7 |
_aPBT _2thema |
|
| 072 | 7 |
_aTDCW _2bic |
|
| 072 | 7 |
_aMBNS _2bic |
|
| 072 | 7 |
_aPS _2bic |
|
| 072 | 7 |
_aPBT _2bic |
|
| 072 | 7 |
_aMAT029000 _2bisac |
|
| 072 | 7 |
_aMED071000 _2bisac |
|
| 072 | 7 |
_aMED090000 _2bisac |
|
| 072 | 7 |
_a615.19 _2bisac |
|
| 100 | 1 | _aHarry Yang | |
| 245 | 1 | 0 | _aEmerging Non-Clinical Biostatistics in Biopharmaceutical Development and Manufacturing |
| 250 | _a1 | ||
| 260 |
_bChapman and Hall/CRC _c20161130 |
||
| 300 | _a386 p | ||
| 520 | _bThe premise of Quality by Design (QbD) is that the quality of the pharmaceutical product should be based upon a thorough understanding of both the product and the manufacturing process. This state-of-the-art book provides a single source of information on emerging statistical approaches to QbD and risk-based pharmaceutical development. A comprehensive resource, it combines in-depth explanations of advanced statistical methods with real-life case studies that illustrate practical applications of these methods in QbD implementation. | ||
| 999 |
_c4630 _d4630 |
||